Skip to main content
Quest Diagnostics

BRCA1 and BRCA2 Testing When a Familial Variant is Reported

2023 BRCA  Symposium, The 9th International Symposium on Hereditary Breast and Ovarian Cancer

Montreal, Canada May 2-5, 2023

Poster presentation: BRCA1 and BRCA2 Testing When a Familial Variant is Reported

Authors: Terhaar C, Johnson R, Brickl A, Hawkins D, Martz J, Fesko Y

Specialties: Oncology, Genetics

Related content

Conference Presentation
Breast Cancer Cohort of the Comprehensive Outcomes for After Cancer Health (COACH) Study: Study+D124 Protocol
On-Demand Webinar
Innovations within Precision Oncology Evolution of a Biomarker a Case Study of KRAS-G12C
On-Demand Webinar
Hereditary Cancer Care Starts in Primary Care

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.